Abstracts tagged "Galectin and rheumatoid arthritis (RA)"

Abstract Number: 2040 • 2018 ACR/ARHP Annual Meeting
Galectin-3 Is a Regulator of 4-1BB/CD137 Activity and Associates with Outcome in Rheumatoid Arthritis.
Morten Aagaard Nielsen¹, Tue Wenzel Kragstrup², Kristian Stengaard-Pedersen³, Kim Hørslev-Petersen⁴, Merete Lund Hetland⁵, Mikkel Østergaard⁶, Peter Junker⁷, Malene Hvid⁸, Ulf Nilsson⁹, John Stegmayr¹⁰, Hakon Leffler¹¹ and Bent Deleuran¹, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Randers Regional Hospital, Randers, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Department of Clinical Medicine, Aarhus, Denmark, ⁴King Christian X Hospital for Rheumatic Diseases, Graasten, Denmark, ⁵Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, The DANBIO Registry, Glostrup, Denmark, ⁶Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ⁷Department of Rheumatology C, Odense University Hospital, Odense, Denmark, ⁸Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁹Deptment of Chemistry, Center for analysis and Synthesis, Lund, Sweden, ¹⁰Department of Laboratory Medicine, Division of Microbiology, Immunology, and Glycobiology (MIG), Lund University, LUND, Sweden, ¹¹Department of Laboratory Medicine, Division of Microbiology, Immunology and Glycobiology - MIG, Lund University, LUND, Sweden
Background/Purpose: Galectin-3 (Gal-3) and the co-stimulatory T cell receptor and glycoprotein 4-1BB are both considered important in inflammation and immune responses. This had led to…
Abstract Number: 2818 • 2018 ACR/ARHP Annual Meeting
Galectin-3 As a Marker of Subclinical Atherosclerosis, Arterial Stiffness and Myocardial Performance in Patients with Rheumatoid Arthritis
Panagiota Anyfanti¹, Eugenia Gkaliagkousi¹, Areti Triantafyllou¹, Eleni Gavriilaki¹, Panagiotis Dolgyras¹, Sophia Chatzimichailidou², Vasiliki Galanopoulou³, Stella Douma¹ and Spyros Aslanidis², ¹3rd Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ²Rheumatology Department-2nd Propedeutic Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ³Rheumatology Department, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece
Background/Purpose: Galectin-3 has emerged as a promising novel biomarker of cardiovascular fibrosis, that can improve cardiovascular risk stratification in high-risk populations. Rheumatoid arthritis (RA) is…
Abstract Number: 1380 • 2017 ACR/ARHP Annual Meeting
Serum Galectin-3 in Rheumatoid Arthritis Compared with Healthy Controls and Subjects with Prediabetes before and after High-Intensity Interval Training
Brian J. Andonian¹, David Bartlett², Virginia B. Kraus³, Janet Huebner², William E. Kraus⁴ and Kim M. Huffman⁵, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Duke University, Durham, NC, ³Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵School of Medicine, Division of Rheumatology, Immunology and Molecular Physiology and Durham VA Medical Center, Duke University, Durham, NC
Background/Purpose: Rheumatoid arthritis (RA) is associated with significant cardiovascular disease (CVD), sarcopenic obesity, and mortality. Galectin-3 is a biomarker associated with inflammation, fibrosis, and increased…
Abstract Number: 2363 • 2017 ACR/ARHP Annual Meeting
Does Galectin-3 Have Utility As a Biomarker of Subclinical Cardiovascular Disease in RA Patients Independently of RA Disease Activity?
Amanda Nussdorf¹, Isabelle Amigues² and Joan Bathon³, ¹Columbia University Medical Center, New York, NY, ²Division of Rheumatology, Columbia University Medical Center, New York, NY, ³Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY
Background/Purpose: Galectin-3 is a beta-galactoside-binding lectin and is a marker of cardiovascular disease (CVD) in the general population. However, galectin-3 level is also elevated in…
Abstract Number: 1306 • 2015 ACR/ARHP Annual Meeting
MRI Erosions in Undifferentiated Arthritis. Different Associations with the Collagen IIA N-Terminal Propeptide (PIIANP) and Galectin-3 in Pre-RA and Other Arthritides
Saida Farah Issa¹, Anne Duer², Mikkel Østergaard³, Hanne Lindegaard¹, Kim Hørslev-Petersen⁴, Merete Lund Hetland⁵, Jakob M. Møller⁶, Anne Friesgaard Christensen⁷ and Peter Junker¹, ¹Department of Rheumatology, Odense University Hospital, Odense, Denmark, ²Department of Rheumatology, Copenhagen University Hospital at Hvidovre, Hvidovre, Denmark, ³Center for Rheumatology and Spine Diseases, Glostrup Hospital, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁴Rheumatology, Research Unit at King Christian X Hospital for Rheumatic Diseases, Graasten, Denmark, ⁵DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, ⁶Department of Radiology, Copenhagen University Hospital Herlev, Herlev, Denmark, ⁷Department of Rheumatology, Vejle Hospital, Vejle, Denmark
Background/Purpose: Galectin-3 has been implicated as a mediator of inflammation and erosive progression in animal arthritis and rheumatoid arthritis(RA). The type IIA procollagen peptide(PIIANP) is…
Abstract Number: 1905 • 2014 ACR/ARHP Annual Meeting
Within-Day Variation and Influence of Physical Exercise on Circulating Galectin-3 in Patients with Rheumatoid Arthritis and Healthy Individuals
Saida Farah Issa¹, Anne Friesgaard Christensen², Tine Lottenburger², Kirsten Junker³, Hanne M. Lindegaard¹, Kim Hoerslev-Petersen⁴ and Peter Junker¹, ¹Department of Rheumatology, Odense University Hospital, Odense, Denmark, ²Department of Rheumatology, Vejle Hospital, Vejle, Denmark, ³Institute of Molecular Medicine, Cardiovascular & Renal Research, University of Southern Denmark, Odense, Denmark, ⁴Rheumatology, Research Unit at King Christian X Hospital for Rheumatic Diseases, Graasten, Graasten, Denmark
Background/Purpose: Galectin-3 has been suggested as a pro-inflammatory mediator in Rheumatoid Arthritis(1). Thus, Galectin-3 is over-expressed in RA-synovitis and bone erosions were significantly decreased in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].